Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Share :
Published: 7 Nov 2023
Views: 35
Rating:
Save
Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Prof Ignace Vergote speaks to ecancer at ESMO 2023 about the innovaTV 301/ENGOT-cx12/GOG-3057 study.

This was a global, randomised, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in second line or third line recurrent or metastatic cervical cancer.

In the study results, tisotumab vedotin showed a statistically significant and clinically meaningful improvement in overall survival, progression free survival, and overall response rate versus chemotherapy, with a manageable and tolerable safety profile in patients with second line or third line recurrent or metastatic cervical cancer.